Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECC 4703

Next Previous
Drug Profile

ECC 4703

Alternative Names: ECC-4703

Latest Information Update: 27 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eccogene
  • Class Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Obesity
  • Phase I Dyslipidaemias

Most Recent Events

  • 16 Mar 2026 Phase-IIa clinical trials in Obesity (Adjunctive treatment) in USA (PO) (NCT07505303)
  • 12 Jan 2026 Eccogene plans a phase I food effect and relative bioavailability trial for Non-alcoholic steatohepatitis (In volunteers) in January 2026 (NCT07334080)
  • 10 Jan 2026 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in Australia (unspecified route) (NCT07334080)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top